DarioHealth today announced it would release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 9, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time.
The global insulin pump market size is expected to grow at a CAGR of 8.46% 2022-2028. The explosion in research and development and published studies about the closed-loop system with insulin pumps in diabetes management gives new insulin pump market growth opportunities. Several hybrid systems are expected to be commercialized in the future associated with insulin delivery.
#insulin pump
#closed loop
The global insulin delivery devices market is poised to expand at 7% CAGR during the forecast period (2023 to 2033). Worldwide insulin delivery device sales are expected to reach US$ 16.8 billion in 2023.
#insulin pen
France Diabetes Market will reach US$ 3.39 Billion in 2028 and expand at a CAGR of 2.75% from 2023 to 2028, according to the publisher. France's statutory health insurance (SHI) covers 100% of it, and the number of covered patients has doubled in the past ten years. Nearly a million are diagnosed with diabetes in France, according to the World Health Organisation (WHO). There is an increasing demand for diabetes monitoring devices due to favourable reimbursement policies, a large population of patients with insulin-dependent diabetes, and the introduction of new products by industry players.
#bgm
#cgm
#insulin pump
According to the publisher, the demand analysis of Global Glucose Biosensor Market size & share revenue was valued at around USD 10.30 Billion in 2021 and is estimated to grow about USD 20.12 billion by 2030, at a CAGR of approximately 8.10% between 2022 and 2030.
Abbott today announced that the U.S. Food and Drug Administration has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems. AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors. The company is partnering with Insulet and Tandem for future integrations in multiple countries, including the U.S. Outside the U.S., Abbott's FreeStyle Libre 3 sensor is already authorized to work with the mylife™ Loop solution from Ypsomed and CamDiab in Germany, with additional launches in the UK, Switzerland and the Netherlands planned for the first half of this year.
#cgm
#closed loop
#insulin pump
Less than two years ago, Bigfoot Biomedical launched its Bigfoot Unity platform in some U.S. states. Just last month, the company made a major play to further bolster this platform. It sold pump-based automated insulin delivery technology patents to pump maker Insulet for $25 million. Further positives followed within weeks, as Bigfoot soon after received FDA clearance for the Android mobile app for Bigfoot Unity. CEO Jeffrey Brewer explained that a “substantial amount” of Bigfoot Biomedical’s early work came on a closed-loop automated insulin delivery (AID) system. However, Bigfoot concluded that it couldn’t carry on with both the AID technology and the Bigfoot Unity platform. Brewer said the next steps for Bigfoot are to take the limited commercial launch to a larger population of people. Currently, the Bigfoot Unity works with the Abbott FreeStyle Libre 2 CGM. With the next-generation FreeStyle Libre 3 receiving FDA clearance last year, Brewer said Bigfoot plans to extend compatibility with future versions when ready.
#cgm
#closed loop
#insulin pump
Sanofi and Voluntis announced today a non-exclusive agreement to deliver digital insulin titration solutions, featuring a mobile phone application designed to help improve decision-making and self-management of type 2 diabetes for people treated with basal insulin. The application will also enable remote monitoring by health care teams. The agreement reinforces the existing alliance between the two companies, established in 2011, by expanding both its scope and geography.
#r&d
#mobile app
Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company to support integration of Lilly’s insulin products into Bigfoot’s systems currently in development. The company anticipates a commercial launch of its first two systems, Bigfoot Inject and Bigfoot Loop, in 2020, pending completion of a pivotal clinical trial and subsequent regulatory approvals.
#product & service
#closed loop
Zealand Pharma and Beta Bionics announce that they have bolstered their collaboration to advance the development of a dual- hormone bionic pancreas utilizing both dasiglucagon (liquid formulation glucagon analog) and insulin. Zealand will invest an initial USD 1.5 million in Beta Bionics. Zealand and Beta Bionics, have been collaborating on the use of of dasiglucagon with the iLet, a dual-hormone bionic pancreas for automated diabetes management. Potential future investments of up to USD 3.5 million are linked to clinical development milestones. The investment is to fund continued development by Beta Bionics on the iLet dual-hormone bionic pancreas towards Phase 2b and Phase 3 development and is made as an equity investment in the Series B offering of Beta Bionics, which has raised an undisclosed sum to date and is ongoing.
#r&d
#closed loop